Machine-learning Based Prediction Model in Primary Immune Thrombocytopenia
NCT05116423 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2022-02-08
Summary
This study developed the first prediction model for risk of critical ITP bleeds for ITP inpatients using a novel machine learning algorithm. This model has been implemented as a web-based model so that clinicians can obtain the estimated probability of critical ITP bleeds for ITP inpatients. The objective of this study is to prospectively and externally validate the risk of critical ITP bleeds in newly admitted ITP patients.
Conditions
Sponsors & Collaborators
-
Affiliated Zhongshan Hospital of Dalian University
collaborator OTHER -
Jiangsu Provincial People's Hospital
collaborator OTHER -
Qilu Hospital of Shandong University
collaborator OTHER -
Shanghai Zhongshan Hospital
collaborator OTHER -
Peking University People's Hospital
lead OTHER
Principal Investigators
-
Xiao-Hui Zhang, MD · Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Collaborative Innovation Center of Hematology
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-11-10
- Primary Completion
- 2022-03-01
- Completion
- 2022-06-30
Countries
- China
Study Locations
More Related Trials
-
Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)
NCT01506414 ·Status: COMPLETED ·Phase: PHASE3
-
Alteration of Different Immune Parameters in Immune Thrombocytopenia (ITP) Patients Receiving Eltrombopag Treatment
NCT01864512 ·Status: WITHDRAWN
-
Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP
NCT07057778 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia
NCT01317966 ·Status: WITHDRAWN
-
Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)
NCT06107582 ·Status: RECRUITING
-
rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP
NCT01525836 ·Status: COMPLETED ·Phase: PHASE3
-
Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
NCT04518475 ·Status: RECRUITING ·Phase: PHASE4
-
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07297563 ·Status: RECRUITING ·Phase: PHASE2
-
Rituximab Combining Bortezomib Versus Rituximab in Management of ITP
NCT03443570 ·Status: UNKNOWN ·Phase: PHASE3
-
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07234019 ·Status: RECRUITING ·Phase: PHASE2
-
A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP)
NCT02137681 ·Status: WITHDRAWN ·Phase: PHASE3
-
Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
NCT04003220 ·Status: UNKNOWN
-
Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia
NCT01727232 ·Status: COMPLETED
-
The Serum Lipid Profiles in ITP: a Retrospective Study
NCT05095896 ·Status: COMPLETED
-
The Study of Different Dose Rituximab in the Treatment of ITP
NCT03258866 ·Status: COMPLETED ·Phase: PHASE4
-
Value of Platelet Indices as Predictive Factor in Thrombocytopenia
NCT05116033 ·Status: UNKNOWN
-
Biologic Characterization of Patients With ITP
NCT05694325 ·Status: RECRUITING ·Phase: NA
-
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
NCT00128713 ·Status: COMPLETED ·Phase: PHASE3
-
High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
NCT01356511 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients
NCT05311930 ·Status: UNKNOWN ·Phase: PHASE4
-
An Investigation of rhTPO With Different Frequencies in the Management of ITP
NCT02139501 ·Status: COMPLETED ·Phase: PHASE3
-
Gut Microbiota in ITP
NCT05118126 ·Status: UNKNOWN
-
Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
NCT01734057 ·Status: WITHDRAWN ·Phase: PHASE3
-
The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.
NCT01101295 ·Status: UNKNOWN
-
An Exploratory Study of Golidocitinib in Adult Patients With ITP
NCT07196163 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2